{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T07:43:59Z","timestamp":1778917439854,"version":"3.51.4"},"reference-count":109,"publisher":"Informa UK Limited","issue":"10","funder":[{"name":"Dracopolous and Hankins Uveitis Funds"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Ocular Immunology and Inflammation"],"published-print":{"date-parts":[[2025,11,26]]},"DOI":"10.1080\/09273948.2025.2584913","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T18:40:52Z","timestamp":1763059252000},"page":"2498-2509","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Immunotherapy and Direct Acting Anti-Cancer Agent Associated-Uveitis"],"prefix":"10.1080","volume":"33","author":[{"given":"Naomi","family":"Warszawski","sequence":"first","affiliation":[{"name":"Drexel University","place":["Philadelphia, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maggie","family":"Feng","sequence":"additional","affiliation":[{"name":"Drexel University","place":["Philadelphia, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anjalee","family":"Bhuyan","sequence":"additional","affiliation":[{"name":"Drexel University","place":["Philadelphia, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Fonollosa","sequence":"additional","affiliation":[{"name":"University of the Basque Country","place":["Barakaldo, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1575-0819","authenticated-orcid":false,"given":"Lucia","family":"Sobrin","sequence":"additional","affiliation":[{"name":"Massachusetts Eye and Ear Infirmary","place":["Boston, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meghan K.","family":"Berkenstock","sequence":"additional","affiliation":[{"name":"Johns Hopkins School of Medicine","place":["Baltimore, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.07.012"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2013.208"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2014.998519"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.0379"},{"issue":"1527","key":"e_1_3_2_6_1","first-page":"83","article-title":"Drug-induced ocular inflammation","volume":"133","author":"Samalia P","year":"2020","unstructured":"Samalia P, Sims J, Niederer R. Drug-induced ocular inflammation. N Z Med J. 2020;133(1527):83\u201394. https:\/\/www.proquest.com\/scholarly-journals\/drug-induced-ocular-inflammation\/docview\/2472332916\/se-2. Accessed July 11, 2025.","journal-title":"N Z Med J"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0483"},{"key":"e_1_3_2_8_1","unstructured":"Tremelimumab [package insert]. FDA; 2022."},{"key":"e_1_3_2_9_1","unstructured":"Rendon A. Appaji Rayi. Nivolumab [Internet]. Nih.gov. StatPearls Publishing; 2024. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK567801\/#article-127327.s8. Accessed October 9 2025."},{"key":"e_1_3_2_10_1","unstructured":"Flynn JP Gerriets V. Pembrolizumab [Internet]. Nih.gov. StatPearls Publishing; 2023. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK546616\/#article-58888.s5. Accessed April 8 2025."},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.07.1461"},{"key":"e_1_3_2_12_1","unstructured":"RUBY Safety Profile | JEMPERLI (dostarlimab-gxly) [Internet]. www.jemperlihcp.com; https:\/\/www.jemperlihcp.com\/safety-profile\/ruby-trial\/."},{"key":"e_1_3_2_13_1","unstructured":"ZYNYZ\u00ae (retifanlimab-dlwr) for SCAC | Official HCP Site [Internet]. Zynyzhcp.com; 2025. https:\/\/www.zynyzhcp.com\/scac\/. Accessed October 9 2025."},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000002181"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12112547"},{"key":"e_1_3_2_16_1","unstructured":"IMFINZI\u00ae (durvalumab) Safety and Adverse Reactions in Metastatic NSCLC [Internet]. Imfinzihcp.com; 2023. https:\/\/www.imfinzihcp.com\/nsclc\/metastatic\/safety.html#isi. Accessed October 9 2025."},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14030336"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-011049"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11174993"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12348-022-00321-2"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2020.1781902"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.joco.2019.05.002"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.11.001"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2019.1583347"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2020.1773867"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000000724"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2020.12.013"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.36401\/JIPO-22-14"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2018.1851"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1159\/000526636"},{"key":"e_1_3_2_31_1","unstructured":"U.S. Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) v5.0. Published November 27 2017. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm. Accessed July 17 2025."},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.60.8448"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1055\/a-1766-6119"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/08820538.2021.1906916"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/1758835921992989"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.05.038"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000050"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1632"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25511"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.4161\/onci.22745"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071823"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.4068\/cmj.2017.53.3.173"},{"key":"e_1_3_2_43_1","unstructured":"Aleem A Shah H. Atezolizumab [Internet]. Nih.gov. StatPearls Publishing. 2024. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK567758\/#article-130748.s5. Accessed October 9 2025."},{"key":"e_1_3_2_44_1","unstructured":"Trametinib [package insert]. FDA; 2013."},{"key":"e_1_3_2_45_1","unstructured":"Cobimetinib [package insert]. FDA; 2015."},{"key":"e_1_3_2_46_1","unstructured":"Binimetinib [package insert]. FDA; 2018."},{"key":"e_1_3_2_47_1","unstructured":"Selumetinib [package insert]. FDA; 2020."},{"key":"e_1_3_2_48_1","unstructured":"Vemurafenib [package insert]. FDA; 2011."},{"key":"e_1_3_2_49_1","unstructured":"Encorafenib [package insert]. FDA; 2018."},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000002451"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.05.008"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.11.027"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.299"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2021.1928714"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-025-03720-6"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12348-015-0049-9"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2024.2401626"},{"key":"e_1_3_2_58_1","volume-title":"EURETINA","author":"Y\u0131ld\u0131r\u0131m B","year":"2021","unstructured":"Y\u0131ld\u0131r\u0131m B, Kalayc\u0131 D, Alp MN. A case of combined MEK and BRAF inhibitor treatment associated retinopathy and uveitis. EURETINA; 2021. [Conference abstract\u2014no journal citation available]."},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/734249"},{"key":"e_1_3_2_60_1","unstructured":"Dabrafenib [package insert]. FDA; 2013."},{"key":"e_1_3_2_61_1","unstructured":"Erlotinib [package insert]. FDA; 2004."},{"key":"e_1_3_2_62_1","unstructured":"Osimertinib [package insert]. FDA; 2004."},{"key":"e_1_3_2_63_1","unstructured":"Gefitinib [package insert]. FDA; 2015."},{"key":"e_1_3_2_64_1","unstructured":"Vandetanib [package insert]. FDA; 2011."},{"key":"e_1_3_2_65_1","unstructured":"Mobocertinib [package insert]. FDA; 2021."},{"key":"e_1_3_2_66_1","unstructured":"Lazertinib [package insert]. FDA; 2024."},{"key":"e_1_3_2_67_1","unstructured":"Dacomitinib [package insert]. FDA; 2018."},{"key":"e_1_3_2_68_1","unstructured":"Cetuximab [package insert]. FDA; 2004."},{"key":"e_1_3_2_69_1","unstructured":"Panitumumab [package insert]. FDA; 2006."},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.NCC.0000281739.65641.6a"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2019-232868"},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.1159\/000444047"},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.29600"},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.1136\/bcr.01.2011.3772"},{"key":"e_1_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2017.03.003"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.1111\/aos.14454"},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2016.09.003"},{"key":"e_1_3_2_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjo.2015.03.013"},{"key":"e_1_3_2_79_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26237411"},{"key":"e_1_3_2_80_1","doi-asserted-by":"publisher","DOI":"10.3390\/kinasesphosphatases3020010"},{"key":"e_1_3_2_81_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28052400"},{"issue":"4","key":"e_1_3_2_82_1","first-page":"173","article-title":"Ibrutinib and the evolution of BTK inhibitors in chronic lymphocytic leukemia","volume":"26","author":"Woyach JA","year":"2019","unstructured":"Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib and the evolution of BTK inhibitors in chronic lymphocytic leukemia. Curr Opin Hematol. 2019;26(4):173\u2013179.","journal-title":"Curr Opin Hematol"},{"key":"e_1_3_2_83_1","unstructured":"Necitumumab [package insert]. FDA; 2015."},{"key":"e_1_3_2_84_1","unstructured":"Ibrutinib [package insert]. FDA; 2013."},{"key":"e_1_3_2_85_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25042208"},{"key":"e_1_3_2_86_1","doi-asserted-by":"publisher","DOI":"10.1177\/11206721211001268"},{"key":"e_1_3_2_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2021.101300"},{"key":"e_1_3_2_88_1","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2023.2295540"},{"key":"e_1_3_2_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.05.009"},{"key":"e_1_3_2_90_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26195847"},{"key":"e_1_3_2_91_1","unstructured":"M\u00fchlegger M. Fda approved antibody-drug conjugates for cancer therapy. Published online. https:\/\/www.susupport.com\/knowledge\/bioconjugates\/fda-approved-antibody-drug-conjugates. Accessed August 16 2023."},{"key":"e_1_3_2_92_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000001805"},{"key":"e_1_3_2_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2016.02.005"},{"key":"e_1_3_2_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.05.007"},{"key":"e_1_3_2_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2023.101155"},{"key":"e_1_3_2_96_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01900"},{"key":"e_1_3_2_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2025.101738"},{"issue":"8","key":"e_1_3_2_98_1","first-page":"4484","article-title":"Characterization and management of ocular toxicities associated with mirvetuximab soravtansine therapy","volume":"66","author":"Haidar AJ","year":"2025","unstructured":"Haidar AJ, Chen JL, Al-Hashimi SK, Ghaffari R, Tsui E. Characterization and management of ocular toxicities associated with mirvetuximab soravtansine therapy. Invest Ophthalmol Vis Sci. 2025;66(8):4484.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_2_99_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1419145"},{"key":"e_1_3_2_100_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12345-021-00012-3"},{"key":"e_1_3_2_101_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1978090"},{"key":"e_1_3_2_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2022.101440"},{"key":"e_1_3_2_103_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-2284"},{"key":"e_1_3_2_104_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01080-8"},{"key":"e_1_3_2_105_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-019-0750-1"},{"key":"e_1_3_2_106_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1777625"},{"key":"e_1_3_2_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30274-8"},{"key":"e_1_3_2_108_1","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2021.1882031"},{"key":"e_1_3_2_109_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.2535"},{"key":"e_1_3_2_110_1","doi-asserted-by":"publisher","DOI":"10.1097\/IIO.0000000000000434"}],"container-title":["Ocular Immunology and Inflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/09273948.2025.2584913","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T17:09:51Z","timestamp":1765386591000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/09273948.2025.2584913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":109,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,11,26]]}},"alternative-id":["10.1080\/09273948.2025.2584913"],"URL":"https:\/\/doi.org\/10.1080\/09273948.2025.2584913","relation":{},"ISSN":["0927-3948","1744-5078"],"issn-type":[{"value":"0927-3948","type":"print"},{"value":"1744-5078","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,13]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ioii20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ioii20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-08-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-29","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}